体外治疗（HA-380 联合高容量血液滤过）在重症 COVID-19 患者中早期清除细胞因子可能预防急性呼吸窘迫综合征进展：病例报告。
Early Cytokine Removal in Critical COVID-19 Patients with Extracorporeal Therapies (HA-380 plus High Volume Hemofiltration) May Prevent Progression of Acute Respiratory Distress Syndrome: Case Report.
机构信息
Critical Care Unit, Carlos Van Buren Hospital, Valparaíso, Chile,
Dialysis and Renal Trasplant Unit, Carlos Van Buren Hospital, Valparaíso, Chile,
出版信息
Blood Purif. 2021;50(4-5):575-577. doi: 10.1159/000512982. Epub 2020 Dec 2.
Abstract
We present the case of a patient who suffered from acute respiratory distress syndrome caused by pneumonia associated with COVID-19 and cytokine release syndrome. This patient received a high-volume hemofiltration plus adsorption, solving the hemodynamic deterioration, pulmonary infiltrates, and gas exchange. Our clinical case proposes that the extracorporeal therapies can have a role in the management of severe COVID-19.
摘要
我们报告了一例由 COVID-19 相关肺炎和细胞因子释放综合征引起的急性呼吸窘迫综合征患者。该患者接受了高容量血液滤过加吸附治疗，解决了血流动力学恶化、肺部浸润和气体交换问题。我们的临床病例表明，体外治疗在严重 COVID-19 的治疗中可能具有一定作用。
相似文献
1
Early Cytokine Removal in Critical COVID-19 Patients with Extracorporeal Therapies (HA-380 plus High Volume Hemofiltration) May Prevent Progression of Acute Respiratory Distress Syndrome: Case Report.
Blood Purif. 2021;50(4-5):575-577. doi: 10.1159/000512982. Epub 2020 Dec 2.
2
Hemoperfusion with CytoSorb as Adjuvant Therapy in Critically Ill Patients with SARS-CoV2 Pneumonia.
Blood Purif. 2021;50(4-5):566-571. doi: 10.1159/000511725. Epub 2020 Nov 12.
3
Early Hemoperfusion for Cytokine Removal May Contribute to Prevention of Intubation in Patients Infected with COVID-19.
Blood Purif. 2021;50(2):257-260. doi: 10.1159/000509107. Epub 2020 Jun 26.
4
Hemoperfusion as a Potential Treatment for Critically Ill COVID-19 Patients with Cytokine Storm.
Blood Purif. 2021;50(3):405-407. doi: 10.1159/000511391. Epub 2020 Nov 10.
5
Cytokine Blood Filtration Responses in COVID-19.
Blood Purif. 2021;50(2):141-149. doi: 10.1159/000508278. Epub 2020 May 28.
6
Continuous venous hemodialysis integrated to the ECMO circuit in critically ill patient with COVID-19, a case report in Morocco.
Pan Afr Med J. 2020 Aug 10;35(Suppl 2):141. doi: 10.11604/pamj.supp.2020.35.141.25332. eCollection 2020.
7
Therapeutic plasma exchange in a critically ill Covid-19 patient.
J Clin Apher. 2021 Feb;36(1):179-182. doi: 10.1002/jca.21830. Epub 2020 Sep 1.
8
Efficacy of the Cytokine Adsorption Therapy in Patients with Severe COVID-19-Associated Pneumonia: Lesson Learned from a Prospective Observational Study.
Blood Purif. 2024;53(1):10-22. doi: 10.1159/000534914. Epub 2023 Nov 2.
9
Severe COVID-19 Infections-Knowledge Gained and Remaining Questions.
JAMA Intern Med. 2021 Jan 1;181(1):9-11. doi: 10.1001/jamainternmed.2020.6047.
10
Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Trials. 2021 Jan 6;22(1):9. doi: 10.1186/s13063-020-04964-1.
引用本文的文献
1
Study on the clinical characteristics, treatment, and outcome influencing factors of severe pneumonia complicated with ARDS.
Medicine (Baltimore). 2024 Nov 8;103(45):e40316. doi: 10.1097/MD.0000000000040316.
2
Hemoadsorption as Adjuvant Therapy in Acute Respiratory Distress Syndrome (ARDS): A Systematic Review and Meta-Analysis.
Biomedicines. 2023 Nov 16;11(11):3068. doi: 10.3390/biomedicines11113068.
3
Microbead-based extracorporeal immuno-affinity virus capture: a feasibility study to address the SARS-CoV-2 pandemic.
Mikrochim Acta. 2023 Feb 18;190(3):95. doi: 10.1007/s00604-023-05671-9.
4
Efficacy Evaluation of High-Volume Hemofiltration in Patients with Severe Acute Respiratory Distress Syndrome.
Evid Based Complement Alternat Med. 2022 Sep 20;2022:9488047. doi: 10.1155/2022/9488047. eCollection 2022.
Zotero 插件